A number of epidemiologic studies of breast cancer risk have classified women who reported undergoing simple premenopausal hysterectomy without bilateral oophorectomy as being postmenopausal at the age when natural menopause has occurred in a high percentage (S:90 percent) of women (1-3). We demonstrate below that this approach to the inclusion of women with simple hysterectomy leads to an underestimate of the effect of age at menopause on breast cancer risk, as well as an underestimate of the effect of hormone replacement therapy (HRT) on breast cancer risk. Other epidemiologic studies of breast cancer have included women with simple hysterectomy in their analyses by setting the woman's age at menopause equal to her age at hysterectomy, with the inclusion of an indicator variable for this category of women (4). We demonstrate below that this approach also leads to biased results, again underestimating the impact of age at menopause and of HRT use on breast cancer risk.
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AGE AT MENOPAUSE
Age at menopause was shown to be an important risk factor for breast cancer in studies conducted in the 1960s (5, 6) , and its relevance has been confirmed by numerous further studies, as reviewed by Kelsey et al. (7) . These studies equated age at menopause with age at the last menstrual period (LMP), and distinguished "natural menopause" from "surgical menopause" due to bilateral oophorectomy (or some other medical procedure). Table 1 shows results reported by Trichopoulos et al. (6) from the study which firmly established the degree of protection from breast cancer associated with menopause; they found an approximately 8 percent increase in breast cancer risk per year of increase in age at LMP. The effect is clearly shown for both natural menopause and surgical menopause (bilateral oophorectomy). Women who had stopped menstruating because of simple hysterectomy (without bilateral oophorectomy) were effectively not considered in these analyses.
INCLUSION OF WOMEN WITH SIMPLE HYSTERECTOMY Effect on estimates of breast cancer risk associated with age at menopause
Let us consider a simplified situation in which women have either a natural menopause or a simple hysterectomy before this time, and no women have menopause due to bilateral oophorectomy. To further simplify matters, let us suppose that there is no HRT use in this population, that all hysterectomies take place at age 35 years, that natural menopause (as measured by LMP) in women who do not have a simple hysterectomy never takes place before age 40 or after age 59, and that its distribution in the population of women without simple hysterectomy is as shown in the second column of table 2.
In approximate agreement with the results shown in table 1, let the relative risks of breast cancer at age 65 years (for example) in naturally postmenopausal women increase steadily over the four age-at-LMP groups (40-44, 45-49, 50-54, and 55-59 years) from 1.0 to 2.0, as shown in the third column of the table. The distribution of breast cancer cases in naturally postmenopausal women is obtained by multiplying the relative risks by the population distribution (of controls) and standardizing to 100 percent. This distribution is shown in the fourth column of table 2. The analysis of data in a case-control or cohort study restricted to these naturally postmenopausal women will, of course, derive the correct estimates of relative risk (subject only to correct adjustment for any other confounding factors, and sampling error).
How does one include the women with simple hysterectomy in the analysis? In the hypothetical situation illustrated here, the method of assigning such women an age at menopause equal to the age at which natural menopause occurs in a high percentage (^90 percent) of women (1-3) would include such women in the 55-59 age-at-LMP group. What does this do to the computed relative risks? It depends on 1) the true "age at menopause" of these women, i.e., the age at which the women with simple hysterectomy would have had their LMP if menses had been observed, and 2) the proportion of such women in the population.
Consider again a simple situation in which the (unobservable) age at LMP of the women with simple hysterectomy has the same distribution as that in naturally postmenopausal women, and assume that the proportion of women who have a simple hysterectomy is 30 percent (approximately as observed in US studies of HRT and breast cancer). The average relative risk (RR) of these women with simple hysterectomy is obtained by multiplying the relative risks in the four age-at-LMP groups by the population distribution of age at LMP: RR = 1.0 X 10 percent + 1.333 X 40 percent + 1.667 X 40 percent + 2.0 X 10 percent = 1.5.
The effect of applying this relative risk to the women with simple hysterectomy assigned to the 55-59 ageat-LMP group is shown in the fifth column of table 3. The relative risks obtained from such an allocation of women with simple hysterectomy are shown in the last column of the table. Note that the relative risk associated with the 55-59 age-at-LMP group is now lower than that associated with the 50-54 age-at-LMP group; i.e., the computed relative risk for the 55-to 59-year age group is substantially incorrect. This method of analysis has led to a sharp underestimate of the overall effect of age at menopause on breast cancer risk.
The effect of this method of including women with simple hysterectomy on the observed relation between age at menopause and breast cancer risk is exacerbated by additional bias in the same direction caused by the fact that hysterectomy, in some women, damages the blood supply to the ovaries. This may lead to an earlier cessation of ovarian function in women with simple hysterectomy, so that their average relative risk is likely to be even lower than the average of 1.5 assumed here.
Effect on estimates of breast cancer risk associated with HRT
Age at menopause is a confounding factor in studies of the effect of HRT on breast cancer risk, since it is a breast cancer risk factor and is invariably negatively associated with duration of HRT use. This is because, at any given age, the maximum duration of possible HRT use is greatest for women whose age at menopause is youngest; this virtually ensures that age at menopause will be negatively associated with duration of HRT use. Furthermore, women who have an early age at menopause may be more likely to use HRT. It is therefore critical to properly adjust for age at menopause when evaluating the effect of HRT on breast cancer risk. For naturally postmenopausal women, this adjustment is made by equating age at menopause with age at LMP. For women who have had a simple hysterectomy, their (hypothetical) age at LMP is, of course, not known, so this cannot be used as a "marker" of age at menopause. However, age at menopause ("cessation" of ovarian function) will still be a confounder in these women, because, as with naturally postmenopausal women, age at the start of (and hence duration of) HRT use will most likely be strongly negatively correlated with actual age at menopause ("cessation" of ovarian function). Including these women with a simple hysterectomy and artificially setting their (hypothetical) age at LMP to a fixed age will lead to an underestimate of the effect of HRT on breast cancer risk.
As an illustration, let us consider again the simplified situation described above, where women either have a natural menopause or a simple hysterectomy, or consider the analysis of the effect of HRT use by women with a simple hysterectomy. Let us further assume an extreme situation in which all women with simple hysterectomy begin HRT at their actual age at menopause ("cessation" of ovarian function) and use it continuously thereafter, and that the distribution of their actual ages at menopause is the same as the distribution of the ages at LMP of naturally postmenopausal women illustrated in table 2. At age 65 years, for example, we will have the situation illustrated in table 4. Row 1 in the table shows that 10 percent of the women with simple hysterectomy (column 2) will have used HRT for an average of 7.5 years (range, 5-9 * Women assumed to have had a simple hysterectomy (no bilateral oophorectomy) at age 35 years, with aO such women assumed to begin HRT at their actual age at menopause ('cessation* of ovarian function) and to continue use of HRT thereafter.
t Numbers in parentheses, range.
years) (column 1); these are the women who will have had an age of menopause in the age range 55-59 years (column 3), and the relative risk of 2.0 associated with this age at menopause is shown in the fourth column. Row 2 shows that 40 percent of the women with simple hysterectomy (column 2) will have used HRT for an average of 12.5 years (range, 10-14 years) (column 1); these are the women who will have had an age of menopause in the age range 50-54 years (column 3), and the relative risk of 1.667 associated with this age at menopause is shown in the fourth column. We see, therefore, that the longer the duration of HRT use the earlier the actual age at menopause and the lower the baseline risk of breast cancer. Analyzing the effect of HRT use on breast cancer risk without adjusting for this negative confounder, as occurs when age at menopause for all women with simple hysterectomy is assigned a fixed value, will lead to a negatively biased estimate of effect. The extent of this downward bias (underestimate) in any particular study will depend on the precise relation between HRT use and actual age at cessation of ovarian function in women with simple hysterectomy, on the relative HRT use among these women and among naturally postmenopausal (and oophorectomized) women, and on the proportion of women with simple hysterectomy in the population.
DISCUSSION
The above analysis shows that including women who have had a simple hysterectomy in an epidemiologic study of breast cancer by assigning them a fixed hypothetical age at menopause in the manner adopted in a number of important studies (1-3) will lead to biased underestimates of the effects both of age at menopause and of HRT use on breast cancer risk. The underestimations of effect are likely to be less than those shown in the hypothetical situations given as illustrations here, but they may well be important when one is attempting to measure the probably small true increments in risk associated with HRT use.
The alternative approach adopted in some studiesconsidering age at simple hysterectomy as "age at LMP" with an indicator variable for hysterectomy included-is also not satisfactory. The relative risks associated with age at LMP will be wrongly increased in the young age-at-LMP groups, again leading to an underestimate of the effect of age at menopause on breast cancer risk. This approach will also lead to the same downward bias in the estimate of the effect of HRT; the arguments developed in describing We also considered the following approach to the inclusion of women with simple hysterectomy: Include women with simple hysterectomy who use HRT, and set their age at menopause at the age at which they first use HRT. This approach assumes that first use of HRT is strongly correlated with age at menopause, and it excludes women with simple hysterectomy who never use HRT, as we have no measure of their age at menopause. Estimates of the effects of HRT will, however, be biased downward because of the random error in the association between age at first use and true age at menopause.
There appears to be no satisfactory way to include women with simple hysterectomy in standard epidemiologic studies of the relation between HRT use and breast cancer risk. The inclusion of such women may appear to lead to tighter confidence intervals around estimates of relative risk, but this is a spurious increase in precision around a biased estimate of risk. Thus, these women are best omitted from such studies. The findings described above may be considered an illustration of the general principle that measurement error in a confounding factor can lead to a biased estimate of the effect under study (8, 9) .
